Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Codiak BioSciences, Inc. (CDAK : NSDQ)
 
 • Company Description   
Codiak BioSciences Inc. is a clinical-stage biopharmaceutical company. It is focused on development of exosome-based therapeutics for spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. Codiak BioSciences Inc. is based in CAMBRIDGE, Mass.

Number of Employees: 102

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.65 Daily Weekly Monthly
20 Day Moving Average: 128,706 shares
Shares Outstanding: 22.49 (millions)
Market Capitalization: $59.61 (millions)
Beta: 4.88
52 Week High: $27.09
52 Week Low: $2.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -31.35% -24.77%
12 Week -43.74% -38.95%
Year To Date -76.21% -71.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
35 CambridgePark Drive Suite 500
-
Cambridge,MA 02140
USA
ph: 617-949-4100
fax: -
investor@codiakbio.com http://www.codiakbio.com
 
 • General Corporate Information   
Officers
Douglas E. Williams - Chief Executive Officer
Steven Gillis - Chairman
Linda C. Bain - Chief Financial Officer
Karen Bernstein - Director
Charles L. Cooney - Director

Peer Information
Codiak BioSciences, Inc. (CORR.)
Codiak BioSciences, Inc. (RSPI)
Codiak BioSciences, Inc. (CGXP)
Codiak BioSciences, Inc. (BGEN)
Codiak BioSciences, Inc. (GTBP)
Codiak BioSciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 192010106
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 22.49
Most Recent Split Date: (:1)
Beta: 4.88
Market Capitalization: $59.61 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.77 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.93 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.11
Price/Cash Flow: -
Price / Sales: 2.66
EPS Growth
vs. Year Ago Period: 29.41%
vs. Previous Quarter: 52.00%
Sales Growth
vs. Year Ago Period: -3.69%
vs. Previous Quarter: 65.05%
ROE
03/31/22 - -146.72
12/31/21 - -135.41
09/30/21 - -169.73
ROA
03/31/22 - -40.44
12/31/21 - -40.42
09/30/21 - -42.42
Current Ratio
03/31/22 - -
12/31/21 - 3.32
09/30/21 - 4.50
Quick Ratio
03/31/22 - -
12/31/21 - 3.32
09/30/21 - 4.50
Operating Margin
03/31/22 - -303.65
12/31/21 - -307.14
09/30/21 - -425.30
Net Margin
03/31/22 - -155.37
12/31/21 - -162.01
09/30/21 - -425.30
Pre-Tax Margin
03/31/22 - -
12/31/21 - -162.01
09/30/21 - -425.29
Book Value
03/31/22 - -
12/31/21 - 2.39
09/30/21 - 1.52
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.48
09/30/21 - 0.75
Debt-to-Capital
03/31/22 - -
12/31/21 - 32.22
09/30/21 - 42.71
 

Powered by Zacks Investment Research ©